文献速递瓣膜病与结构性心脏病

低外科风险主动脉瓣狭窄患者TAVI与SAVR八年结局

Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement.
PubMed 文献 · Eur Heart J · 2021-01-01

NOTION试验将280例症状性重度主动脉瓣狭窄且低外科风险患者随机分配至TAVI或SAVR,随访8年。两组全因死亡、卒中或心肌梗死复合终点风险及人工瓣膜衰竭风险均无显著差异,TAVI组结构性瓣膜退化风险低于SAVR组。

要点

  • 低外科风险重度主动脉瓣狭窄患者TAVI与SAVR的8年死亡、卒中、心梗风险相似。
  • TAVI组结构性瓣膜退化风险低于SAVR组,但人工瓣膜衰竭风险无差异。
  • 该结果支持在低外科风险人群中TAVI可作为SAVR的替代选择。

核心结论

  • 低外科风险重度主动脉瓣狭窄患者随机接受TAVI或SAVR后8年全因死亡、卒中、心肌梗死及人工瓣膜衰竭风险无显著差异。
  • TAVI组结构性瓣膜退化风险低于SAVR组。

研究设计与样本

  • NOTION试验为随机对照试验,共纳入280例症状性重度主动脉瓣狭窄患者,随机分配至TAVI组(n=145)或SAVR组(n=135)。
  • 基线平均年龄79.1±4.8岁,平均STS评分3.0±1.7%。
  • 随访8年,评估临床状态、超声心动图、结构性瓣膜退化及衰竭(采用标准化定义)。

主要发现

  • 8年时全因死亡、卒中或心肌梗死复合终点估计风险TAVI组54.5%、SAVR组54.8%(P=0.94)。
  • 全因死亡估计风险TAVI组51.8%、SAVR组52.6%(P=0.90)。
  • 卒中估计风险TAVI组8.3%、SAVR组9.1%(P=0.90)。
  • 心肌梗死估计风险TAVI组6.2%、SAVR组3.8%(P=0.33)。
  • 结构性瓣膜退化风险TAVI组13.9%、SAVR组28.3%(P=0.0017);人工瓣膜衰竭风险TAVI组8.7%、SAVR组10.5%(P=0.61)。

临床怎么用

  • 对于低外科风险的重度主动脉瓣狭窄患者,TAVI与SAVR的8年硬终点相似,TAVI的结构性瓣膜退化风险更低,可作为个体化决策依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aims of the study were to compare clinical outcomes and valve durability after 8 years of follow-up in patients with symptomatic severe aortic valve stenosis at low surgical risk treated with either transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR). METHODS AND RESULTS: In the NOTION trial, patients with symptomatic severe aortic valve stenosis were randomized to TAVI or SAVR. Clinical status, echocardiography, structural valve deterioration, and failure were assessed using standardized definitions. In total, 280 patients were randomized to TAVI (n = 145) or SAVR (n = 135). Baseline characteristics were similar, including mean age of 79.1 ± 4.8 years and a mean STS score of 3.0 ± 1.7%. At 8-year follow-up, the estimated risk of the composite outcome of all-cause mortality, stroke, or myocardial infarction was 54.5% after TAVI and 54.8% after SAVR (P = 0.94). The estimated risks for all-cause mortality (51.8% vs. 52.6%; P = 0.90), stroke (8.3% vs. 9.1%; P = 0.90), or myocardial infarction (6.2% vs. 3.8%; P = 0.33) were similar after TAVI and SAVR. The risk of structural valve deterioration was lower after TAVI than after SAVR (13.9% vs. 28.3%; P = 0.0017), whereas the risk of bioprosthetic valve failure was similar (8.7% vs. 10.5%; P = 0.61). CONCLUSIONS: In patients with severe aortic valve stenosis at low surgical risk randomized to TAVI or SAVR, there were no significant differences in the risk for all-cause mortality, stroke, or myocardial infarction, as well as the risk of bioprosthetic valve failure after 8 years of follow-up. CLINICAL TRIAL REGISTRATION: URL: http://www.ClinicalTrials.gov. Unique identifier: NCT01057173.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Jørgensen TH, Thyregod HGH, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J. 2021. PMID: 34179981. doi:10.1093/eurheartj/ehab375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。